Literature DB >> 6313181

The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients.

F R Hirsch, K Osterlind, H H Hansen.   

Abstract

Three hundred seventy-five consecutive patients treated with intensive chemotherapy in the same institution are included in this study in order to evaluate the prognostic significance of the World Health Organization's (WHO) subclassification of small cell lung cancer. Morphologic subtyping, based on primary biopsy specimens, was obtained in 200 patients. Oat cell type was diagnosed in 106 patients (53%), while intermediate subtype was diagnosed in 93 patients (47%), including 27 patients (14%) with small cell/large cell morphologic features. One patient had combined oat cell type. No difference in survival period was observed between the group of patients classified as oat cell versus the group with intermediate subtype. However, a significantly shorter survival period was demonstrated for patients with small cell/large cell features compared with patients with pure small cell carcinoma (median 168 days versus 280 days, P less than 0.01). It is concluded that there is no difference in survival period between patients with oat cell and intermediate subtype of small cell lung cancer using the criteria of the WHO. However, it might be of prognostic importance to identify patients with tumors demonstrating small cell/large cell features.

Entities:  

Mesh:

Year:  1983        PMID: 6313181     DOI: 10.1002/1097-0142(19831201)52:11<2144::aid-cncr2820521128>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies).

Authors:  W Theuer; O Selawry; K Karrer
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 2.  Neuroendocrine differentiation in lung tumours.

Authors:  M N Sheppard
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

3.  Chemotherapy for small cell lung neoplasms.

Authors:  N Ibrahim; J Briggs; K Jeyasingham; C P Forrester-Wood; E Andrianopoulos
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-02

Review 4.  Studying lung cancer in the laboratory: 3--Use of cell lines to investigate the biology of lung cancer.

Authors:  R J Fergusson; J F Smyth
Journal:  Thorax       Date:  1987-12       Impact factor: 9.139

5.  Differential expression of intermediate filament proteins distinguishes classic from variant small-cell lung cancer cell lines.

Authors:  J L Broers; D N Carney; L de Ley; G P Vooijs; F C Ramaekers
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

6.  Value of adequate fixation for accurate histological interpretation.

Authors:  M Kudo
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

7.  v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer.

Authors:  M Mabry; T Nakagawa; B D Nelkin; E McDowell; M Gesell; J C Eggleston; R A Casero; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

8.  Single primary lung cancer consisting of three cancer cell types (small cell carcinoma, adenocarcinoma, and squamous cell carcinoma) in which each had metastasized to different lymph nodes.

Authors:  Hiroo Shikata; Yoshimichi Ueda; Shuji Tsuchishima; Toshimichi Nonaka; Yoh Watanabe; Junichi Matsubara
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-05

9.  Tumor heterogeneity in lung cancer based on light microscopic features. A retrospective study of a consecutive series of 200 patients, treated surgically.

Authors:  F R Hirsch; G Ottesen; J Pødenphant; J Olsen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

10.  Intracerebral and subcutaneous xenografts of human SCLC in the nude rat: comparison of monoclonal antibody localization and tumor infiltrating lymphocytes.

Authors:  J W Bulte; K G Go; F Zuiderveen; T H The; L de Leij
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.